Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Change in Accured Expenses came in at $4.7 million in Q1 2026, up 236.76% year-on-year from $1.4 million in Q1 2025, and up 145.48% quarter-over-quarter from -$10.3 million in Q4 2025.

Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $4.7 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 236.76% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 170.27% increase from a year earlier, with the FY2025 full-year figure at $8.5 million, down 19.31% from the prior year.
  • Change in Accured Expenses grew to $4.7 million in Q1 2026 per SRRK's latest filing, from -$10.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $16.4 million in Q2 2025 and bottomed at -$10.3 million in Q4 2025.
  • The 5-year median for Change in Accured Expenses is $1.6 million (2022), against an average of $1.6 million.
  • Biggest YoY gain for Change in Accured Expenses was 3230.83% in 2025; the steepest drop was 663.35% in 2025.
  • Year by year, Change in Accured Expenses stood at $1.6 million in 2022, then soared by 91.26% to $3.0 million in 2023, then plunged by 39.01% to $1.8 million in 2024, then tumbled by 663.35% to -$10.3 million in 2025, then surged by 145.48% to $4.7 million in 2026.
  • Per Business Quant, the three latest SRRK Change in Accured Expenses figures stand at $4.7 million (Q1 2026), -$10.3 million (Q4 2025), and $5.8 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Oculis Holding AG 66,981.90 Bn 66,981.62 Bn - 1.13 Mn
2 Nanobiotix 1,930.48 Bn 1,930.42 Bn - -
3 Akari Therapeutics 1,071.19 Bn 1,071.19 Bn - 931,000.00
4 BeOne Medicines 468.55 Bn 463.76 Bn 1.35 Bn -16.82 Mn
5 Vertex Pharmaceuticals 123.04 Bn 115.79 Bn 2.59 Bn 23.10 Mn
6 Regeneron Pharmaceuticals 70.31 Bn 61.56 Bn 3.31 Bn 107.70 Mn
7 Belite Bio 63.40 Bn 63.40 Bn - -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.67 Bn 34.66 Bn 959.66 Mn -176.03 Mn
10 Scholar Rock Holding 6.28 Bn 6.28 Bn - 4.68 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.68 Mn
Mar 31, 2026 4.68 Mn
Dec 31, 2025 -10.30 Mn
Dec 31, 2025 -10.30 Mn
Sep 30, 2025 5.80 Mn
Sep 30, 2025 5.80 Mn
Jun 30, 2025 16.42 Mn
Jun 30, 2025 16.42 Mn
Mar 31, 2025 -3.43 Mn
Mar 31, 2025 -3.43 Mn
Dec 31, 2024 1.83 Mn
Dec 31, 2024 1.83 Mn
Sep 30, 2024 7.25 Mn
Sep 30, 2024 7.25 Mn
Jun 30, 2024 493,000.00
Jun 30, 2024 493,000.00
Mar 31, 2024 963,000.00
Mar 31, 2024 963,000.00
Dec 31, 2023 3.00 Mn
Dec 31, 2023 3.00 Mn